Account Information

  • My Account

    Manage all your subscriptions, update your address, email preferences and change your password.

  • Help Center

    Get answers to common service questions, ask the analyst or contact our customer service department.

  • My Stock Talk Profile

    Update your stock talk name and/or picture.


Five-Minute Fortunes

Five-Minute FortunesFor the past 20 months, a small group of regular Americans have been making profits of $7,001… $23,335… and even $46,670. Month in and month out. Just from following one simple sentence of instructions in a trade alert. The next alert is set to come out in just a few days. Find out how to get it here.




Blooming Small-Cap IPOs

By Linda McDonough on May 11, 2015

By Linda McDonough

Lilacs and forsythia aren’t the only things blooming this May.  Young companies eager for cash are budding all over.  Although only three deals have priced so far this month, at least another 16 are waiting in the wings.  If all these deals are priced, May would record the highest number of deals so far this year.

It should be no surprise to anyone watching the stock market that the bulk of these deals are biotechs. These tender-footed labs are no fools.  Hungry for the cash devoured by their research and development budgets, they are eager to rake in the riches being awarded most biotech companies.  Twenty of the 62 IPOs priced to date have been biotechs.

Starting the craze: Spark Therapeutics (Nasdaq: ONCE) launched a January IPO that opened up 96% from its deal price and traded as high as $77 this year before retreating to $60, a level still 160% higher than the $23 offering price.  Eager buyers sent many biotech IPOs skyrocketing after pricing, some doubling within days.

A puncture to the group in April has deflated many of those gains but the group overall is still up since pricing. The class of 2015 biotech IPOs are up an average of 6% from their deal price.

Collegium Pharmaceutical (Nasdaq: COLL), based in Canton, Mass., started trading on May 7th and looks quite interesting.  Unlike all the other biotechs in queue, Collegium has a product submitted to the FDA. In February it filed a new drug application (NDA) for an abuse-deterrent, extended-release version of oxycodone. Collegium has done head-to-head trials with Oxycontin OP, the abuse-deterrent version of oxycodone currently on the market, and shown it was more effective.

Oxycontin OP currently has sales of $2.5 billion in the U.S.  Collegium’s DETERx technology can be used on other potentially abusable painkillers as well.  Collegium has a market cap of $250 million.

Bojangles (Nasdaq: BOJA), a restaurant chain famous for their Cajun fried chicken and buttermilk biscuits, made its market debut on May 8th.  Investors have been starry eyed for high growth restaurant stocks recently.  For example, Shake Shack (NYSE: SHAK) trades at $66, an outrageous valuation based on the 5 cents it is expected to earn this year and the 9 cents anticipated in 2016.  Zoe’s Kitchen (NYSE: ZOES) has been described as a Mediterranean version of Chipotle Mexican Grill.  Although officially “cheaper” than Shake Shack, Zoe’s trades at 640 times 2015 estimates and despite tripling earnings in 2016, still trades at 200 times that number!  Clearly investors are willing to pay up for growth.

With such a broad umbrella for valuation, Bojangles should have no problem finding buyers of its stock. Bojangles has put up some impressive growth despite its fairly large base of 635 stores.  Store growth has been compounding at 7% for the past 5 years but revenue is growing faster at 13% as units generate higher sales.  Operating income has been growing roughly 15% and the company disclosed preliminary results for the March quarter which showcases 18% growth in operating income.  

With an average check of $6.68, Bojangles believes they deliver the lowest tab to fast food diners nationwide.  Low prices and terrific value helped keep customers loyal during the recession. Same store comparable sales have increased every single quarter since June 2010.  Earnings per share increased only slightly in 2014 due to an increased higher tax rate.  However based on the 18% growth seen in the first quarter of this year it’s quite possible that earnings follow that trajectory for the entire year.

Bojangles has an $865 million market cap and and trades for 24 times 2014 earnings.  Formal estimates for 2015 will not be released until the company’s quiet period ends but should mirror the 18% growth seen in the first quarter and leave plenty of upside for this stock.  

Another notable deal set to price the week of May 11th is Arcadia Biosciences (Nasdaq: RKDA).  Arcadia develops genetically modified food traits for crops. Although competition is fierce from Monsanto and Syngenta, Arcadia is focusing on the niche of nitrogen efficiency and drought tolerance.  The company is losing money currently with little revenue growth. However progress in developing and proving more seed traits which should result in higher sales.  Arcadia’s market cap will be $530 million at $14, the middle of its $13-$15 pricing range.

You might also enjoy…


Obscure Tax Law Forces This Company to Pay Out 90% of its Profits

A 50-year-old loophole is forcing one company to pay out $9 of every $10 it makes from ironclad contracts with the U.S. Government.

In fact, over the past seven years, it’s made payments ranging from a few dollars… to tens of thousands of dollars… 30 times. Without a single cut! 

Most folks don’t even know this company exists, but the ones that do are making a mint.

Like Ted B., who’s set to receive a check for $1,096 just a few days from now.

Merrill H., a 58-year-old from New York, has collected over $3,385 so far. 

And retirees Beth and Terry P. have raked in $16,555.

I’ve put together a special report that will give you all the details, including simple instructions on how to get your name on the payout list before the next cutoff date.

You can get your copy here.

Stock Talk — Post a comment Comment Guidelines

Our Stock Talk section is reserved for productive dialogue pertaining to the content and portfolio recommendations of this service. We reserve the right to remove any comments we feel do not benefit other readers. If you have a general investment comment not related to this article, please post to our Stock Talk page. If you have a personal question about your subscription or need technical help, please contact our customer service team. And if you have any success stories to share with our analysts, they’re always happy to hear them. Note that we may use your kind words in our promotional materials. Thank you.

You must be logged in to post to Stock Talk OR create an account.

Create a new Investing Daily account

  • - OR -

* Investing Daily will use any information you provide in a manner consistent with our Privacy Policy. Your email address is used for account verification and will remain private.